NCT05043987View on ClinicalTrials.gov

Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 16, 2022

Primary Completion Date

November 16, 2022

Study Completion Date

November 16, 2022

Conditions
Pancreatic CancerGastric Cancer
Interventions
DRUG

CPO102

Anti-claudin 18.2 Antibody-MMAE Drug Conjugate

Sponsors
All Listed Sponsors
collaborator

CSPC Megalith Biopharmaceutical Co.,Ltd.

INDUSTRY

lead

Conjupro Biotherapeutics, Inc.

INDUSTRY

NCT05043987 - Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers | Biotech Hunter | Biotech Hunter